These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27716588)

  • 1. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience.
    Russo V; Di Napoli L; Bianchi V; Tavoletta V; De Vivo S; Cavallaro C; Vecchione F; Rago A; Sarubbi B; Calabrò P; Nigro G; D'Onofrio A
    Int J Cardiol; 2016 Dec; 224():454-455. PubMed ID: 27716588
    [No Abstract]   [Full Text] [Related]  

  • 2. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study.
    Russo V; Rago A; Papa AA; Bianchi V; Tavoletta V; DE Vivo S; Cavallaro C; Nigro G; D'Onofrio A
    Minerva Cardioangiol; 2018 Feb; 66(1):1-5. PubMed ID: 28948752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
    Shevelev VI; Kanorsky SG
    Klin Med (Mosk); 2015; 93(7):30-6. PubMed ID: 26596056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Klein HH
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1309-11. PubMed ID: 23737116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
    Averkov OV
    Kardiologiia; 2011; 51(7):53-7. PubMed ID: 21878086
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    Yadlapati A; Groh C; Passman R
    Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticoagulation in atrial fibrillation before cardioversion].
    Stellbrink C; Hanrath P
    Dtsch Med Wochenschr; 1999 Apr; 124(13):407. PubMed ID: 10226651
    [No Abstract]   [Full Text] [Related]  

  • 13. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study).
    Lip GY; Gitt AK; Le Heuzey JY; Bash LD; Morabito CJ; Bernhardt AA; Sisk CM; Chazelle F; Crijns HJ;
    Am J Cardiol; 2014 Feb; 113(3):480-4. PubMed ID: 24332698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anticoagulation and electrical cardioversion of chronic atrial fibrillation: proposal for an abbreviated protocol].
    Antonielli E; Pizzuti A; Gandolfo N; Sclavo M; Tanga M; Riva G; Leonardi G; Bassignana A; Di Leo M
    G Ital Cardiol; 1997 Aug; 27(8):803-10. PubMed ID: 9312508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin.
    Akdeniz B; Türker S; Oztürk V; Badak O; Okan T; Aslan O; Kozan O; Kirimli O; Aytekin D; Bariş N; Güneri S
    Int J Cardiol; 2005 Jan; 98(1):49-55. PubMed ID: 15676166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transesophageal echocardiography-guided cardioversion].
    Saarela E; Koskela V; Strandberg M; Airaksinen KE; Niemelä M; Raatikainen MJ
    Duodecim; 2004; 120(13):1575-81. PubMed ID: 15326964
    [No Abstract]   [Full Text] [Related]  

  • 20. [Termination of paroxysm of atrial fibrillation conversion using oral propafenone after unsuccessful electrical cardioversion].
    Kupriianova OG; Pavlov AV; Vaniev SB; Doshchitsin VL
    Kardiologiia; 2012; 52(4):95-6. PubMed ID: 22839523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.